Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin-3

Copyright information:Taken from "Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin"http://www.molecular-cancer.com/content/6/1/66Molecular Cancer 2007;6():66-66.Published online 22 Oct 2007PMCID:PMC2134932.ngle treatments or combinations of 2.12 μM cisplatin and/or 1.01 μg/ml Lexatumumab or fractions/multiples of those concentrations at a constant ratio from 0.25- to 4-fold. Responses were determined by MTT assay after 72 h and bars indicate standard deviations. Synergy was quantified by Combination Index (CI) analysis and expressed as CI versus fraction affected. By this method, CI1 indicates antagonism. 96% confidence intervals are shown on CI plots. Data shown represent mean values from three independent experiments. and . Concurrent treatment with Mapatumumab (Mapa) or Lexatumumab monoclonal antibodies enhance the cytotoxicity of cisplatin in H28 cells. Experiments were performed as described under , except that cisplatin, Mapatumumab and Lexatumumab were used at a concentration of 6.61 μM, 0.13 μg/ml and 0.40 μg/ml, respectively, and fractions/multiples thereof. Data represent means of three independent experiments and bars indicate standard deviations.